The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index
Open accessAbstract
Despite efforts spanning four decades, the therapeutic potential of thyroid hormone receptor (TR) agonists as lipid-lowering and anti-obesity agents remains largely unexplored in humans because of dose-limiting cardiac effects and effects on the thyroid hormone axis (THA), muscle metabolism, and bone turnover. TR agonists selective for the TRβ isoform exhibit modest cardiac sparing in rodents and primates but are unable to lower lipids without inducing TRβ-mediated suppression of the THA. Herein, we describe a cytochrome P450-activated prodrug of a phosphonate-containing TR agonist that exhibits increased TR activation in the liver relative to extrahepatic tissues and an improved therapeutic index. Pharmacokinetic studies in rats demonstrated that the prodrug (2 R ,4 S )-4-(3-chlorophenyl)-2-[(3,5-dimethyl-4-(4′-hydroxy-3′-isopropylbenzyl)phenoxy)methyl]-2-oxido-[1,3,2]-dioxaphosphonane (MB07811) undergoes first-pass hepatic extraction and that cleavage of the prodrug generates the negatively charged TR agonist (3,5-dimethyl-4-(4′-hydroxy-3′-isopropylbenzyl)phenoxy)methylphosphonic acid (MB07344), which distributes poorly into most tissues and is rapidly eliminated in the bile. Enhanced liver targeting was further demonstrated by comparing the effects of MB07811 with 3,5,3′-triiodo- l -thyronine (T 3 ) and a non-liver-targeted TR agonist, 3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid (KB-141) on the expression of TR agonist-responsive genes in the liver and six extrahepatic tissues. The pharmacologic effects of liver targeting were evident in the normal rat, where MB07811 exhibited increased cardiac sparing, and in the diet-induced obese mouse, where, unlike KB-141, MB07811 reduced cholesterol and both serum and hepatic triglycerides at doses devoid of effects on body weight, glycemia, and the THA. These results indicate that targeting TR agonists to the liver has the potential to lower both cholesterol and triglyceride levels with an acceptable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiological and Molecular Basis of Thyroid Hormone Action
Yen, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1097 · Cited by 2,011
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
The c-erb-A gene encodes a thyroid hormone receptor
Weinberger, C., Thompson, C. C., Ong, E. S., Lebo, R., Gruol, D. J., & Evans, R. M. (1986) · Nature · doi:10.1038/324641a0 · Cited by 1,477
The c-erb-A protein is a high-affinity receptor for thyroid hormone
Sap, J., Muñoz, A., Damm, K., Goldberg, Y., Ghysdael, J., Leutz, A., Beug, H., & Vennström, B. (1986) · Nature · doi:10.1038/324635a0 · Cited by 1,330
Thyroid Hormone Receptors: Multiple Forms, Multiple Possibilities*
LAZAR, M. A. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-2-184 · Cited by 1,071
Welt, F. G. P., & Edelman, E. R. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)90003-x · Cited by 863
Parle, J. V., Maisonneuve, P., Sheppard, M. C., Boyle, P., & Franklyn, J. A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06067-6 · Cited by 669
Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1
Wikstrom, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.455 · Cited by 513
The Thyroid: A Fundamental and Clinical Text
WERNER, S. C. (1956) · The American Journal of the Medical Sciences · doi:10.1097/00000441-195610000-00020 · Cited by 460
Forrest, D., Hanebuth, E., Smeyne, R. J., Everds, N., Stewart, C. L., Wehner, J. M., & Curran, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00664.x · Cited by 440
A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor
Chiellini, G., Apriletti, J. W., Yoshihara, H. A., Baxter, J. D., Ribeiro, R. C. J., & Scanlan, T. S. (1998) · Chemistry & Biology · doi:10.1016/s1074-5521(98)90168-5 · Cited by 278
Trost, S. U., Swanson, E., Gloss, B., Wang-Iverson, D. B., Zhang, H., Volodarsky, T., Grover, G. J., Baxter, J. D., Chiellini, G., Scanlan, T. S., et al. (2000) · Endocrinology · doi:10.1210/endo.141.9.7681 · Cited by 272
Health Care–Associated Bloodstream Infections
Kaye, K. S., Friedman, N. D., & Sexton, D. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00018 · Cited by 232
Grover, G. J., Mellström, K., Ye, L., Malm, J., Li, Y.-L., Bladh, L.-G., Sleph, P. G., Smith, M. A., George, R., Vennström, B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633737100 · Cited by 222
Drug Uptake Systems in Liver and Kidney
van Montfoort, J., Hagenbuch, B., Groothuis, G., Koepsell, H., Meier, P., & Meijer, D. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489460 · Cited by 221
Johansson, L., Rudling, M., Scanlan, T. S., Lundåsen, T., Webb, P., Baxter, J., Angelin, B., & Parini, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504379102 · Cited by 200
Thyroid hormone excess and glucose intolerance
Dimitriadis, G., & Raptis, S. (2001) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2001-18584 · Cited by 179
The thermogenic effect of thyroid hormone and its clinical implications
Silva, J. E. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00010 · Cited by 173
Cholesterol metabolism in hypothyroidism and hyperthyroidism in man.
Abrams, J. J., & Grundy, S. M. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35375-x · Cited by 172
Liu, Y.-Y., Schultz, J. J., & Brent, G. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306120200 · Cited by 168
Hormone Selectivity in Thyroid Hormone Receptors
Wagner, R. L. (2001) · Molecular Endocrinology · doi:10.1210/me.15.3.398 · Cited by 167
Erion, M. D., Reddy, K. R., Boyer, S. H., Matelich, M. C., Gomez-Galeno, J., Lemus, R. H., Ugarkar, B. G., Colby, T. J., Schanzer, J., & van Poelje, P. D. (2004) · Journal of the American Chemical Society · doi:10.1021/ja031818y · Cited by 165
Self-citationGrover, G. J., Egan, D. M., Sleph, P. G., Beehler, B. C., Chiellini, G., Nguyen, N.-H., Baxter, J. D., & Scanlan, T. S. (2004) · Endocrinology · doi:10.1210/en.2003-0973 · Cited by 163
Erion, M. D., van Poelje, P. D., Dang, Q., Kasibhatla, S. R., Potter, S. C., Reddy, M. R., Reddy, K. R., Jiang, T., & Lipscomb, W. N. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502983102 · Cited by 162
Self-citationThyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β1
Liu, Y., Li, Y.-L., Mellström, K., Mellin, C., Bladh, L.-G., Koehler, K., Garg, N. K., Collazo, A., Litten, C., Husman, B., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021080f · Cited by 157
Prodrugs : challenges and rewards
Stella, V. J. (2007) · Cited by 153
Theory and practice of site-specific drug delivery
Tomlinson, E. (1987) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(87)90001-9 · Cited by 148
Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse
Zavacki, A. M., Ying, H., Christoffolete, M. A., Aerts, G., So, E., Harney, J. W., Cheng, S.-Y., Larsen, P. R., & Bianco, A. C. (2005) · Endocrinology · doi:10.1210/en.2004-1392 · Cited by 138
Friesema, E. C. H., Jansen, J., & Visser, T. J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330228 · Cited by 133
A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity
Underwood, A. H., Emmett, J. C., Ellis, D. A., Flynn, S. B., Leeson, P. D., Benson, G. M., Novelli, R., Pearce, N. J., & Shah, V. P. (1986) · Nature · doi:10.1038/324425a0 · Cited by 131
Moreno, M., Lanni, A., Lombardi, A., & Goglia, F. (1997) · The Journal of Physiology · doi:10.1111/j.1469-7793.1997.529bb.x · Cited by 123
Lanni, A., Beneduce, L., Lombardi, A., Moreno, M., Boss, O., Muzzin, P., Giacobino, J., & Goglia, F. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00061-7 · Cited by 120
Liver-Targeted Drug Delivery Using HepDirect Prodrugs
Erion, M. D., van Poelje, P. D., MacKenna, D. A., Colby, T. J., Montag, A. C., Fujitaki, J. M., Linemeyer, D. L., & Bullough, D. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075903 · Cited by 119
Self-citationTissue-Specific Actions of Thyroid Hormone: Insights From Animal Models
Brent, G. A. (2000) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010056202122 · Cited by 114
Metabolism of plasma triglycerides in hypothyroidism and hyperthyroidism in man.
Abrams, J. J., Grundy, S. M., & Ginsberg, H. N. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35374-8 · Cited by 112
The Thyroid A Fundamental and Clinical Text
(1957) · Postgraduate Medical Journal · doi:10.1136/pgmj.33.380.296-a · Cited by 110
Hashimoto, K., Yamada, M., Matsumoto, S., Monden, T., Satoh, T., & Mori, M. (2006) · Endocrinology · doi:10.1210/en.2006-0116 · Cited by 93
Ness, G. C., & Lopez, D. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.0061 · Cited by 87
Hepatic Lipogenesis and Cholesterol Synthesis in Hyperthyroid Patients
Cachefo, A., Boucher, P., Vidon, C., Dusserre, E., Diraison, F., & Beylot, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.7981 · Cited by 74
Mynatt, R. L., Park, E., Thorngate, F. E., Das, H., & Cook, G. A. (1994) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1006/bbrc.1994.1791 · Cited by 72
The effect of altered thyroid function on the ultrastructure of the human liver
Klion, F. M., Segal, R., & Schaffner, F. (1971) · The American Journal of Medicine · doi:10.1016/0002-9343(71)90220-8 · Cited by 66
Hansson, P., Valdemarsson, S. V., & Nilsson‐Ehle, P. (1983) · Hormone and Metabolic Research · doi:10.1055/s-2007-1018751 · Cited by 64
Yokoyama, N., Walker, G. N., Main, A. J., Stanton, J. L., Morrissey, M. M., Boehm, C., Engle, A. R., Neubert, A. D., & Wasvary, J. M. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00004a015 · Cited by 54
Hartong, R., Wiersinga, W. M., & Lamers, W. H. (1987) · Endocrinology · doi:10.1210/endo-120-6-2460 · Cited by 18
Cited by
Mechanisms of thyroid hormone action
Brent, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60047 · Cited by 1,244
Direct effects of thyroid hormones on hepatic lipid metabolism
Sinha, R. A., Singh, B. K., & Yen, P. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.10 · Cited by 660
Prodrugs of Phosphates and Phosphonates
Hecker, S. J., & Erion, M. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701260b · Cited by 414
Self-citationNuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
The relationship between type 2 diabetes mellitus and related thyroid diseases
Wang, C. (2013) · Journal of Diabetes Research · doi:10.1155/2013/390534 · Cited by 273
Metadata
- Authors
- Erion, M. D., Cable, E. E., Ito, B. R., Jiang, H., Fujitaki, J. M., Finn, P. D., Zhang, B.-H., Hou, J., Boyer, S. H., van Poelje, P. D., & Linemeyer, D. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-09-25
- Volume
- 104
- Issue
- 39
- Pages
- 15490-15495
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2029473474
- Cited by
- 271
- References
- 44
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.